ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW | Market Cap | 19.98T +13.3% |
| Revenue (ttm) | 203.76B +34.4% |
| Net Income | 130.19B +4.6% |
| EPS | 1,960.14 -15.7% |
| Shares Out | 53.56M |
| PE Ratio | 190.29 |
| Forward PE | 61.95 |
| Dividend | 371.00 (0.11%) |
| Ex-Dividend Date | n/a |
| Volume | 695,514 |
| Open | 352,000 |
| Previous Close | 343,500 |
| Day's Range | 352,000 - 385,500 |
| 52-Week Range | 286,000 - 569,000 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 458,000.00 (+22.79%) |
| Earnings Date | Aug 11, 2026 |
About ALTEOGEN
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]
Financial Performance
In 2025, ALTEOGEN's revenue was 215.86 billion, an increase of 109.87% compared to the previous year's 102.85 billion. Earnings were 141.67 billion, an increase of 127.57%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for 196170 stock is "Buy." The 12-month stock price target is ₩458,000, which is an increase of 22.79% from the latest price.
News
ALTEOGEN Q1 Net Income Declines
(RTTNews) - ALTEOGEN Inc. (196170.KQ) reported first quarter net income attributable to shareholders of the parent company of 71.7 billion Korean won, a 13.8% decrease compared to 83.2 billion won, a ...
Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics
(RTTNews) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive license agreeme...
FDA Clears Merck's One-Minute Cancer Shot
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE: MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration i...